Page last updated: 2024-11-05

indolizine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Indolizine is a bicyclic heterocyclic compound containing a fused pyrrole and pyridine ring. It is a versatile building block for the synthesis of various bioactive compounds, including alkaloids, antitumor agents, and antibacterial agents. Indolizine derivatives have shown promising biological activities, such as anti-inflammatory, anti-cancer, and antimicrobial properties. The unique electronic and structural features of indolizine contribute to its diverse biological activity. Its synthesis involves various methods, including the Fischer indole synthesis, the Paal-Knorr synthesis, and the ring-closing metathesis reaction. Research on indolizine focuses on exploring its potential as a therapeutic agent, understanding its biological activity, and developing new synthetic methods for its derivatives. Due to its rich chemistry and potential for drug development, indolizine remains an active area of research.'

Cross-References

ID SourceID
PubMed CID9230
CHEMBL ID3622747
CHEBI ID35583
SCHEMBL ID7913
MeSH IDM0107736

Synonyms (28)

Synonym
pyrrolo[1,2-a]pyridine
274-40-8
CHEBI:35583
indolizin
pyrrocoline
inchi=1/c8h7n/c1-2-6-9-7-3-5-8(9)4-1/h1-7
indolizine
bdbm50123663
chembl3622747 ,
AKOS005254677
pyrrolo(1,2-a)pyridine
unii-b48fmh8yfq
b48fmh8yfq ,
P1943
4h-indolizine
4-azaindene
FT-0631895
AB01491
SCHEMBL7913
pyrrocolin
DTXSID50181818
mfcd00030189
Q910641
A876934
D94752
EN300-209020
AS-77407
CS-0155664

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
mancude organic heterobicyclic parent
indolizines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)IC50 (µMol)25.00000.04002.099810.0000AID1250678
Polyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)Ki25.00000.01001.70778.1000AID1250681
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (25)

Processvia Protein(s)Taxonomy
ossificationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
negative regulation of adaptive immune responsePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
phosphatidylethanolamine biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
inflammatory responsePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
positive regulation of cell-substrate adhesionPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
fatty acid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
bone mineralizationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
positive regulation of actin filament polymerizationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
response to endoplasmic reticulum stressPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cellular response to interleukin-13Polyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
wound healingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
apoptotic cell clearancePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cellular response to calcium ionPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
regulation of engulfment of apoptotic cellPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate bindingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
lipid dropletPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytoplasmic side of plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1250681Competitive inhibition of human 15-LOX1 using linoleic acid as substrate after 10 mins by Lineweaver-Burk plot analysis2015Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19
Rational Development of a Potent 15-Lipoxygenase-1 Inhibitor with in Vitro and ex Vivo Anti-inflammatory Properties.
AID1250678Inhibition of 15-LOX1 (unknown origin)2015Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19
Rational Development of a Potent 15-Lipoxygenase-1 Inhibitor with in Vitro and ex Vivo Anti-inflammatory Properties.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (58)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (5.17)18.7374
1990's1 (1.72)18.2507
2000's17 (29.31)29.6817
2010's30 (51.72)24.3611
2020's7 (12.07)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.05 (24.57)
Research Supply Index4.08 (2.92)
Research Growth Index5.23 (4.65)
Search Engine Demand Index54.53 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (40.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.72%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other57 (98.28%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]